


## CLAIMS

The following set of claims replaces all the previous set of claims.

1. (Original) A compound of Formula (I):



wherein,

R<sub>1</sub> is:

(i) hydrogen; or

(ii)  $-\text{SO}_2\text{R}_{10}$ ,

(iii) wherein R<sub>10</sub> is:

halo; hydroxy; OR<sub>11</sub>; OR<sub>12</sub>; amino; NHR<sub>11</sub>; N(R<sub>11</sub>)<sub>2</sub>; NHR<sub>12</sub>; N(R<sub>12</sub>)<sub>2</sub>; aralkylamino; or

C<sub>1</sub>-C<sub>12</sub> alkyl optionally substituted with halo, hydroxy, oxo, nitro, OR<sub>11</sub>, OR<sub>12</sub>, acyloxy, amino, NHR<sub>11</sub>; N(R<sub>11</sub>)<sub>2</sub>; NHR<sub>12</sub>; N(R<sub>12</sub>)<sub>2</sub>, aralkylamino, mercapto, thioalkoxy, S(O)R<sub>11</sub>, S(O)R<sub>12</sub>, SO<sub>2</sub>R<sub>11</sub>, SO<sub>2</sub>R<sub>12</sub>, NHSO<sub>2</sub>R<sub>11</sub>, NHSO<sub>2</sub>R<sub>12</sub>, sulfate, phosphate, cyano, carboxyl, C(O)R<sub>11</sub>, C(O)R<sub>12</sub>, C(O)OR<sub>11</sub>, C(O)NH<sub>2</sub>, C(O)NHR<sub>11</sub>, C(O)N(R<sub>11</sub>)<sub>2</sub>, C<sub>3</sub>-C<sub>10</sub> cycloalkyl containing 0-3 R<sub>13</sub>, C<sub>3</sub>-C<sub>10</sub> heterocyclyl containing 0-3 R<sub>13</sub>, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>5</sub>-C<sub>10</sub> cycloalkenyl, C<sub>5</sub>-C<sub>10</sub> heterocycloalkenyl, C<sub>6</sub>-C<sub>20</sub> aryl containing 0-3 R<sub>14</sub>, or heteroaryl containing 0-3 R<sub>14</sub>; or

$C_3$ - $C_{10}$  cycloalkyl,  $C_3$ - $C_{10}$  heterocyclyl,  $C_5$ - $C_{10}$  cycloalkenyl, or  $C_5$ - $C_{10}$  heterocycloalkenyl optionally substituted with one or more halo, hydroxy, oxo,  $OR_{11}$ ,  $OR_{12}$ , acyloxy, nitro, amino,  $NHR_{11}$ ,  $N(R_{11})_2$ ,  $NHR_{12}$ ,  $N(R_{12})_2$ , aralkylamino, mercapto, thioalkoxy,  $S(O)R_{11}$ ,  $S(O)R_{12}$ ,  $SO_2R_{11}$ ,  $SO_2R_{12}$ ,  $NHSO_2R_{11}$ ,  $NHSO_2R_{12}$ , sulfate, phosphate, cyano, carboxyl,  $C(O)R_{11}$ ,  $C(O)R_{12}$ ,  $C(O)OR_{11}$ ,  $C(O)NH_2$ ,  $C(O)NHR_{11}$ ,  $C(O)N(R_{11})_2$ , alkyl, haloalkyl,  $C_3$ - $C_{10}$  cycloalkyl containing 0-3  $R_{13}$ ,  $C_3$ - $C_{10}$  heterocyclyl containing 0-3  $R_{13}$ ,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $C_5$ - $C_{10}$  cycloalkenyl,  $C_5$ - $C_{10}$  heterocycloalkenyl,  $C_6$ - $C_{20}$  aryl heteroaryl containing 0-3  $R_{14}$ , or  $C_6$ - $C_{20}$  heteroaryl containing 0-3  $R_{14}$ ; or

$C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl, aryl, or heteroaryl optionally substituted with one or more halo, hydroxy,  $OR_{11}$ ,  $OR_{12}$ , acyloxy, nitro, amino,  $NHR_{11}$ ,  $N(R_{11})_2$ ,  $NHR_{12}$ ,  $N(R_{12})_2$ , aralkylamino, mercapto, thioalkoxy,  $S(O)R_{11}$ ,  $S(O)R_{12}$ ,  $SO_2R_{11}$ ,  $SO_2R_{12}$ ,  $NHSO_2R_{11}$ ,  $NHSO_2R_{12}$ , sulfate, phosphate, cyano, carboxyl,  $C(O)R_{11}$ ,  $C(O)R_{12}$ ,  $C(O)OR_{11}$ ,  $C(O)NH_2$ ,  $C(O)NHR_{11}$ ,  $C(O)N(R_{11})_2$ , alkyl, haloalkyl,  $C_3$ - $C_{10}$  cycloalkyl containing 0-3  $R_{13}$ ,  $C_3$ - $C_{10}$  heterocyclyl containing 0-3  $R_{13}$ ,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $C_5$ - $C_{10}$  cycloalkenyl,  $C_5$ - $C_{10}$  heterocycloalkenyl,  $C_6$ - $C_{20}$  aryl containing 0-3  $R_{14}$ , or  $C_6$ - $C_{20}$  heteroaryl containing 0-3  $R_{14}$ ; or

(iii)  $-C(O)R_{10}$ , wherein  $R_{10}$  is defined as above; or

(iv)  $-C(R_{10})_2(R_{15})$ , wherein  $R_{10}$  is defined as above;  $R_{15}$  is hydrogen,  $R_{10}$ , or  $R_{15}$  and  $R_2$  taken together forms a double bond between the carbon and nitrogen atoms to which they are attached; or

(v)  $R_1$  and  $R_2$  taken together forms a heterocyclyl of 3-10 ring atoms optionally substituted with  $R_{10}$ ;

$R_2$  is hydrogen, or  $R_2$  and  $R_{15}$  taken together forms a double bond between the carbon and nitrogen atoms to which they are attached, or  $R_2$  and  $R_1$  taken together forms a heterocyclyl of 3-10 ring atoms optionally substituted with  $R_{10}$ ;

$R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$  and  $R_7$  are each independently hydrogen,  $C_1$ - $C_6$  alkyl,  $C_6$ - $C_{12}$  aralkyl, or  $C_1$ - $C_6$  acyl;

$R_8$  is  $-(CH_2)_xCH_3$ ;

R<sub>9</sub> is a linear or branched C<sub>3</sub>-C<sub>100</sub> alkyl;

R<sub>11</sub> is C<sub>1</sub>-C<sub>20</sub> alkyl optionally substituted with halo, hydroxy, alkoxy, amino, alkylamino, dialkylamino, sulfate, or phosphate;


R<sub>12</sub> is aryl optionally substituted with halo, haloalkyl, hydroxy, alkoxy, nitro, amino, alkylamino, dialkylamino, sulfate, or phosphate;

Each R<sub>13</sub> is independently halo, halo alkyl, hydroxy, alkoxy, oxo, amino, alkylamino, dialkylamino, sulfate, or phosphate;

Each R<sub>14</sub> is independently halo, halo alkyl, hydroxy, alkoxy, nitro, amino, alkyl amino, dialkylamino, sulfate, or phosphate; and

x is 1-100.

2. (Original) The compound of claim 1 wherein x is 24 and R<sub>9</sub> is *n*-tetradecyl.
3. (Original) The compound of claim 2 wherein R<sub>1</sub> is SO<sub>2</sub>R<sub>10</sub>.
4. (Original) The compound of claim 3 wherein R<sub>10</sub> is aryl substituted with N(R<sub>11</sub>)<sub>2</sub>;
5. (Original) The compound of claim 4 wherein R<sub>10</sub> is:




6. (Original) The compound of claim 2 wherein R<sub>1</sub> is C(O)R<sub>10</sub>.

7. (Original) The compound of claim 6 wherein R<sub>10</sub> is C<sub>1</sub>-C<sub>6</sub> alkyl substituted with halo, hydroxy, oxo, nitro, OR<sub>11</sub>, OR<sub>12</sub>, acyloxy, amino, NHR<sub>11</sub>, N(R<sub>11</sub>)<sub>2</sub>, NHR<sub>12</sub>, N(R<sub>12</sub>)<sub>2</sub>, aralkylamino, mercapto, thioalkoxy, S(O)R<sub>11</sub>, S(O)R<sub>12</sub>, SO<sub>2</sub>R<sub>11</sub>, SO<sub>2</sub>R<sub>12</sub>, NSO<sub>2</sub>R<sub>11</sub>, NSO<sub>2</sub>R<sub>12</sub>, sulfate, phosphate, cyano, carboxyl, C(O)R<sub>11</sub>, C(O)R<sub>12</sub>, C(O)OR<sub>11</sub>, C(O)NH<sub>2</sub>, C(O)NHR<sub>11</sub>, C(O)N(R<sub>11</sub>)<sub>2</sub>, C<sub>3</sub>-C<sub>10</sub> cycloalkyl containing 0-3 R<sub>13</sub>, C<sub>3</sub>-C<sub>10</sub> heterocyclyl containing 0-3 R<sub>13</sub>, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>5</sub>-C<sub>10</sub> cycloalkenyl, C<sub>5</sub>-C<sub>10</sub> heterocycloalkenyl, C<sub>6</sub>-C<sub>20</sub> aryl containing 0-3 R<sub>14</sub>, or C<sub>6</sub>-C<sub>20</sub> heteroaryl containing 0-3 R<sub>14</sub>;


8. (Original) The compound of claim 7 wherein R<sub>10</sub> is C<sub>1</sub>-C<sub>6</sub> alkyl substituted with NSO<sub>2</sub>R<sub>12</sub>.

9. (Original) The compound of claim 8 wherein R<sub>12</sub> is:




10. (Original) The compound of claim 7, wherein R<sub>10</sub> is alkyl substituted with C(O)R<sub>12</sub>.

11. (Original) The compound of claim 10 wherein R<sub>12</sub> is:



12. (Original) The compound of claim 7 wherein R<sub>10</sub> is alkyl is substituted with C<sub>5</sub>-C<sub>10</sub> heterocyclyl containing 0-3 R<sub>13</sub>.
13. (Original) The compound of claim 12 wherein the heterocyclyl is:





14. (Cancelled).
15. (Cancelled).
16. (Cancelled).
17. (Cancelled).
18. (Original) A method of stimulating NKT cells comprising contacting an NKT cell with a compound of Formula (I) and a CD1 protein.
19. (Original) The method of claim 18 wherein the protein is CD1d.
20. (Cancelled).

21. (Cancelled).

22. (Cancelled).

23. (Cancelled).

24. (Original) A method of making a compound of Formula (I) comprising: (i) converting a compound of Formula (III) to a compound of Formula (IV):



and (ii) contacting a compound of Formula (IV) with *R*<sub>1</sub>-LG to afford a compound of Formula (I), wherein:

*R*<sub>1</sub> is:

(i)  $-\text{SO}_2\text{R}_{10},$

wherein  $R_{10}$  is:

halo; hydroxy;  $OR_{11}$ ;  $OR_{12}$ ; amino;  $NHR_{11}$ ;  $N(R_{11})_2$ ;  $NHR_{12}$ ;  $N(R_{12})_2$ ; aralkylamino; or

$C_1-C_{12}$  alkyl optionally substituted with halo, hydroxy, oxo, nitro,  $OR_{11}$ ,  $OR_{12}$ , acyloxy, amino,  $NHR_{11}$ ,  $N(R_{11})_2$ ,  $NHR_{12}$ ,  $N(R_{12})_2$ , aralkylamino, mercapto, thioalkoxy,  $S(O)R_{11}$ ,  $S(O)R_{12}$ ,  $SO_2R_{11}$ ,  $SO_2R_{12}$ ,  $NHSO_2R_{11}$ ,  $NHSO_2R_{12}$ , sulfate, phosphate, cyano, carboxyl,  $C(O)R_{11}$ ,  $C(O)R_{12}$ ,  $C(O)OR_{11}$ ,  $C(O)NH_2$ ,  $C(O)NHR_{11}$ ,  $C(O)N(R_{11})_2$ ,  $C_3-C_{10}$  cycloalkyl containing 0-3  $R_{13}$ ,  $C_3-C_{10}$  heterocyclyl containing 0-3  $R_{13}$ ,  $C_2-C_6$  alkenyl,  $C_2-C_6$  alkynyl,  $C_5-C_{10}$  cycloalkenyl,  $C_5-C_{10}$  heterocycloalkenyl,  $C_6-C_{20}$  aryl containing 0-3  $R_{14}$ , or  $C_6-C_{20}$  heteroaryl containing 0-3  $R_{14}$ ; or

$C_3-C_{10}$  cycloalkyl,  $C_3-C_{10}$  heterocyclyl,  $C_5-C_{10}$  cycloalkenyl, or  $C_5-C_{10}$  heterocycloalkenyl optionally substituted with one or more halo, hydroxy, oxo,  $OR_{11}$ ,  $OR_{12}$ , acyloxy, nitro, amino,  $NHR_{11}$ ,  $N(R_{11})_2$ ,  $NHR_{12}$ ,  $N(R_{12})_2$ , aralkylamino, mercapto, thioalkoxy,  $S(O)R_{11}$ ,  $S(O)R_{12}$ ,  $SO_2R_{11}$ ,  $SO_2R_{12}$ ,  $NHSO_2R_{11}$ ,  $NHSO_2R_{12}$ , sulfate, phosphate, cyano, carboxyl,  $C(O)R_{11}$ ,  $C(O)R_{12}$ ,  $C(O)OR_{11}$ ,  $C(O)NH_2$ ,  $C(O)NHR_{11}$ ,  $C(O)N(R_{11})_2$ , alkyl, halo alkyl,  $C_3-C_{10}$  cycloalkyl containing 0-3  $R_{13}$ ,  $C_3-C_{10}$  heterocyclyl containing 0-3  $R_{13}$ ,  $C_2-C_6$  alkenyl,  $C_2-C_6$  alkynyl,  $C_5-C_{10}$  cycloalkenyl,  $C_5-C_{10}$  heterocycloalkenyl,  $C_6-C_{20}$  aryl containing 0-3  $R_{14}$ , or  $C_6-C_{20}$  heteroaryl containing 0-3  $R_{14}$ ; or

$C_2-C_6$  alkenyl,  $C_2-C_6$  alkynyl, aryl, or heteroaryl optionally substituted with one or more halo, hydroxy,  $OR_{11}$ ,  $OR_{12}$ , acyloxy, nitro, amino,  $NHR_{11}$ ,  $N(R_{11})_2$ ,  $NHR_{12}$ ,  $N(R_{12})_2$ , aralkylamino, mercapto, thioalkoxy,  $S(O)R_{11}$ ,  $S(O)R_{12}$ ,  $SO_2R_{11}$ ,  $SO_2R_{12}$ ,  $NHSO_2R_{11}$ ,  $NHSO_2R_{12}$ , sulfate, phosphate, cyano, carboxyl,  $C(O)R_{11}$ ,  $C(O)R_{12}$ ,  $C(O)OR_{11}$ ,  $C(O)NH_2$ ,  $C(O)NHR_{11}$ ,  $C(O)N(R_{11})_2$ , alkyl, halo alkyl,  $C_3-C_{10}$  cycloalkyl containing 0-3  $R_{13}$ ,  $C_3-C_{10}$  heterocyclyl containing 0-3  $R_{13}$ ,  $C_2-C_6$  alkenyl,  $C_2-C_6$  alkynyl,  $C_5-C_{10}$  cycloalkenyl,  $C_5-C_{10}$  heterocycloalkenyl,  $C_6-C_{20}$  aryl containing 0-3  $R_{14}$ , or  $C_6-C_{20}$  heteroaryl containing 0-3  $R_{14}$ ; or

(ii)  $-C(O)R_{10}$ , wherein  $R_{10}$  is defined as above; or

(iii)  $-C(R_{10})_2(R_{15})$ , wherein  $R_{10}$  is defined as above;  $R_{15}$  is hydrogen,  $R_{10}$ , or  $R_{15}$  and  $R_2$  taken together forms a double bond between the carbon and nitrogen atoms to which they are attached; or

$R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$ , and  $R_7$  are each independently hydrogen,  $C_1$ - $C_6$  alkyl,  $C_6$ - $C_{12}$  aralkyl, or  $C_1$ - $C_6$  acyl;

$R_8$  is  $-(CH_2)_xCH_3$ ;

$R_9$  is a linear or branched  $C_3$ - $C_{100}$  alkyl;

$R_{11}$  is  $C_1$ - $C_{20}$  alkyl optionally substituted with halo, hydroxy, alkoxy, amino, alkylamino, dialkylamino, sulfate, or phosphate;


$R_{12}$  is aryl optionally substituted with halo, halo alkyl, hydroxy, alkoxy, nitro, amino, alkylamino, dialkylamino, sulfate, or phosphate;

Each  $R_{13}$  is independently halo, halo alkyl, hydroxy, alkoxy, oxo, amino, alkylamino, dialkylamino, sulfate, or phosphate;

Each  $R_{14}$  is independently halo, halo alkyl, hydroxy, alkoxy, nitro, amino, alkylamino, dialkylamino, sulfate, or phosphate;

$x$  is 1-100;

$LG$  is halo,  $-OSO_2R_{16}$ ,  $B(OH)_2$ , or



$R_{16}$  is alkyl, halo alkyl or aryl optionally substituted with alkyl, halo or nitro.

25. (Original) A pharmaceutical composition comprising a compound of Formula (I) and a pharmaceutically acceptable carrier.